PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease (NCT05928039)
PATHFINDER: A Pragmatic, Active-comparator, Parallel-group, Randomized Trial to Evaluate the Optimal First-line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
🩺 Plain-English Summary (8th-Grade Level)
There are currently three classes of biologic treatments approved in Canada for the management of moderate-to-severe Crohn's disease: anti-tumor necrosis factor \[TNF\] alpha, anti-integrin, and anti-interleukin \[IL\]-23 targeted agents. The purpose of this trial is to determine which of these three classes of biologics results in the highest percentage of patients with small bowel (ileal) Crohn's disease entering into endoscopic remission without needing corticosteroids at 1 year. Endoscopic remission means that the ulcers in the small bowel from Crohn's disease have healed. All treatments in this trial are approved by Health Canada. No experimental drugs will be included.
Who can join: Review the eligibility criteria below.
Location: University of Calgary — Calgary, Alberta
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (20 Sites)
- University of Calgary — Calgary, Alberta
- University of Alberta IBD Clinic — Edmonton, Alberta
- GI Research Institute (G.I.R.I) — Vancouver, British Columbia
- West Coast Gastroenterology — Vancouver, British Columbia
- Nova Scotia Health Victoria — Halifax, Nova Scotia
- GNRR Digestive Clinics and Research Center Inc. — Brampton, Ontario
- Rajbir Rai Medical Corporation — Brantford, Ontario
- McMaster University — Hamilton, Ontario
- London Health Sciences Centre — London, Ontario
- West GTA Research Inc. — Mississauga, Ontario
- ABP Research Services Corp. — Oakville, Ontario
- Taunton Surgical Center — Oshawa, Ontario
- The Ottawa Hospital Research Institute — Ottawa, Ontario
- Thunder Bay Regional Health Research Institute — Thunder Bay, Ontario
- Mount Sinai Hospital — Toronto, Ontario
- TIDHI Clinic — Toronto, Ontario
- Centre Hospitalier de l'Université de Montréal (CHUM) — Montreal, Quebec
- Hôpital du Sacré-Cœur-de-Montréal — Montreal, Quebec
- Research Institute of the McGill University Health Centre (MUHC) — Montreal, Quebec
- Université de Sherbrooke — Sherbrooke, Quebec
📞 Contact the Study Coordinator
Phone: (226) 919-6959
Email: harsha.ashton@alimentiv.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Crohn Disease
- Safety and Efficacy of EcoActive on Intestinal Adherent Invasive E. Coli in Patients With Inactive Crohn's Disease — Lutherville, Maryland
- Proactive Infliximab Optimization Using a Pharmacokinetic Dashboard Versus Standard of Care in Patients With Inflammatory Bowel Disease: The OPTIMIZE Trial — New Haven, Connecticut
- A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease — Portland, Oregon
- Resistant Starch in Pediatric Inflammatory Bowel Disease (Crohn's Disease or Ulcerative Colitis) — Ottawa, Ontario
- A Long-term Extension Study of Ustekinumab in Pediatric Participants — Atlanta, Georgia
- Biomarkers of Intestinal Fibrosis in Small Bowel Crohn's Disease — Atlanta, Georgia
Explore by condition: All Crohn Disease clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.